Beam Therapeutics Inc. (BEAM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Beam Therapeutics Inc. (BEAM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
BEAM - Beam Therapeutics Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$48.00
DETAILS
HIGH:
$80.00
LOW:
$26.00
MEDIAN:
$40.00
CONSENSUS:
$48.00
UPSIDE:
67.60%
Stock News
Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances
Beam Therapeutics NASDAQ: BEAM Chief Executive Officer John Evans said the company is advancing its base-editing platform across hematology and liver disease programs, with a potential biologics license application for its sickle cell disease candidate possible as early as the end of this year.
Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
Presentation Features Additional Data from the Single-dose Cohorts of the Phase 1/2 Trial, Including Detailed Safety Results, Efficacy Durability and Reduction in Human Neutrophil Elastase Activity Post-BEAM-302 Treatment Presentation Features Additional Data from the Single-dose Cohorts of the Phase 1/2 Trial, Including Detailed Safety Results, Efficacy Durability and Reduction in Human Neutrophil Elastase Activity Post-BEAM-302 Treatment
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?
Beam Therapeutics develops precision genetic medicines using base editing technology to target serious inherited diseases.
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1 PR Newswire DURHAM, N.C., May 13, 2026
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1
The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease. DURHAM, N.C.
Beam Therapeutics: Base Editing Is Moving From Platform Story To Regulatory Asset Story
Beam Therapeutics is transitioning from a scientific platform to a late-stage genetic medicine company with a clear commercial bridge. BEAM's $1.2B cash position supports a runway into mid-2029, enabling pivotal programs in sickle cell disease (Risto-cel) and AATD (BEAM-302). Risto-cel targets process efficiency and efficacy in SCD, with a potential BLA submission by year-end 2026; BEAM-302 pursues accelerated approval in AATD.
Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference
CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, will present at the 2026 RBC Capital Markets Healthcare Conference on Wednesday, May 20, 2026, at 10:30 a.m. ET in New York.
Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel's Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026
CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated biomarker data from the BEACON Phase 1/2 clinical trial of ristoglogene autogetemcel (risto-cel) in sickle cell disease (SCD) at the European Hematology Association 2026 Congress (EHA2026), taking place June 11-14, 2026, in Stockholm, Sweden. Risto-cel is an investigational autologous cell therapy with a potential best-in-class profile for the treatment of SCD.
BEAM's Q1 Loss Wider Than Expected, Revenues Beat Estimates
Beam Therapeutics Q1 revenues beat estimates as its gene-editing pipeline advanced, with key updates across the SCD, AATD and PKU programs.
Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Beats Revenue Estimates
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to a loss of $1.24 per share a year ago.
Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
Recent BEAM-302 Topline Data in Alpha-1 Antitrypsin Deficiency (AATD) Demonstrate Strong Single-dose Safety and Efficacy Profile, with 60 mg Selected as Optimal Biological Dose; Global Pivotal Cohort Expected to Initiate in Second Half of 2026 Data from Phase 1/2 BEACON Clinical Trial of Risto-cel in Sickle Cell Disease Published in April 1 Issue of the New England Journal of Medicine; U.S. Biologics License Application (BLA) Submission Expected as Early as Year-End 2026 Investigational New Drug (IND) Application for BEAM-304 in PKU and Data from BEAM-301 in GSDIa Anticipated in 2026 Ended First Quarter 2026 with $1.2 Billion in Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans into mid-2029 CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported first quarter 2026 financial results and provided updates across the company's hematology and genetic disease franchises.
Concurrent Investment Advisors LLC Invests $2.13 Million in Beam Therapeutics Inc. $BEAM
Concurrent Investment Advisors LLC acquired a new stake in Beam Therapeutics Inc. (NASDAQ: BEAM) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 76,825 shares of the company's stock, valued at approximately $2,130,000. Concurrent Investment Advisors LLC owned approximately 0.08% of Beam Therapeutics
Jim Cramer: This Tech Stock Is A 'Winner', Snap Does Not Have Growth
On CNBC's “Mad Money Lightning Round,” Jim Cramer said Ondas Inc (NASDAQ:ONDS) is losing a lot of money and added that he would rather have to find something new and different that is distinct, while he doesn't see anything distinct about Ondas.
3 Biotech Stocks That Could Benefit from the Patent Cliff
Biotechnology stocks have seen a spike in merger and acquisition (M&A) activity. In March 2026 alone, there were 10 deals valued at approximately $31.5 billion.
Colossal’s Ben Lamm Says Invasive Species Is a $5.4 Trillion Problem. Here’s His Solution
Invasive species represent a $5.4 trillion global problem, with U.S. economic impact alone exceeding $500 billion annually. That's according to Ben Lamm, CEO of Colossal Biosciences. On episode 245 of the Moonshots with Peter Diamandis podcast, Lamm made the case that gene drive technology is the only scalable, humane answer. "In New Zealand, in Australia,... Colossal's Ben Lamm Says Invasive Species Is a $5.4 Trillion Problem. Here's His Solution
Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors.
CEO John Evans sold 30,078 company shares for a transaction value of ~$739,000 on April 1, 2026. The sale represented 2.5% of his direct holdings.
Beam Therapeutics (NASDAQ:BEAM) Insider Amy Simon Sells 6,700 Shares
Beam Therapeutics Inc. (NASDAQ: BEAM - Get Free Report) insider Amy Simon sold 6,700 shares of the business's stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $24.58, for a total transaction of $164,686.00. Following the transaction, the insider directly owned 102,735 shares of the company's stock, valued
Beam Therapeutics (NASDAQ:BEAM) Insider Christine Bellon Sells 5,956 Shares
Beam Therapeutics Inc. (NASDAQ: BEAM - Get Free Report) insider Christine Bellon sold 5,956 shares of Beam Therapeutics stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $24.58, for a total value of $146,398.48. Following the sale, the insider owned 109,711 shares in the company, valued at $2,696,696.38.
Beam Therapeutics (NASDAQ:BEAM) President Giuseppe Ciaramella Sells 11,810 Shares
Beam Therapeutics Inc. (NASDAQ: BEAM - Get Free Report) President Giuseppe Ciaramella sold 11,810 shares of the company's stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $24.58, for a total transaction of $290,289.80. Following the completion of the transaction, the president owned 218,406 shares in
Price Targets
H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)
$80.00
(was $27.11)
Patrick Trucchio
·
H.C. Wainwright
Beam Therapeutics price target lowered to $39 from $40 at Bernstein
$39.00
(was $31.58)
William Pickering
·
Tudor Pickering
Beam Therapeutics price target raised to $26 from $22 at RBC Capital
$26.00
(was $30.83)
RBC Capital
Beam Therapeutics initiated with a Buy at Canaccord
$74.00
(was $27.88)
Canaccord Genuity
Beam Therapeutics Inc (BEAM) PT Raised at Bernstein Following Positive Regulatory Update
$41.00
(was $31.00)
William Pickering
·
Tudor Pickering
Beam Therapeutics price target raised to $41 from $37 at Bernstein
$41.00
(was $30.96)
Bernstein
UBS Starts Beam Therapeutics Inc (BEAM) at Neutral
$28.00
(was $28.34)
Michael Yee
·
UBS
Beam Therapeutics initiated with an Outperform at Evercore ISI
$35.00
(was $23.32)
Evercore ISI
Beam Therapeutics initiated with a Buy at Jefferies
$41.00
(was $27.86)
Jefferies
Beam Therapeutics price target lowered to $55 from $78 at Guggenheim
$55.00
(was $15.99)
Debjit Chattopadhyay
·
Guggenheim
Beam Therapeutics price target raised to $25 from $24 at Scotiabank
$25.00
(was $25.10)
Scotiabank
Bernstein SocGen Group Upgrades Beam Therapeutics Inc (BEAM) to Outperform
$37.00
(was $27.08)
William Pickering
·
Tudor Pickering
Leerink Partners Upgrades Beam Therapeutics Inc (BEAM) to Outperform, 'we see a far more attractive risk/reward'
$39.00
(was $24.34)
Rick Bienkowski
·
Leerink Partners
BMO Capital on Beam Therapeutics Inc (BEAM): 'We see BEAM-101 clinical data as positive'
$57.00
(was $24.34)
Kostas Biliouris
·
BMO Capital
Beam Therapeutics Inc (BEAM) PT Raised to $69 at Stifel
$69.00
(was $23.34)
Benjamin Burnett
·
Stifel Nicolaus
Cantor Fitzgerald Initiates Coverage On Beam Therapeutics with Overweight Rating, Announces Price Target of $62
$62.00
(was $43.45)
Cantor Fitzgerald
BMO Capital Upgrades Beam Therapeutics Inc (BEAM) to Outperform as Risk/Reward 'Skewed to Upside'
$66.00
(was $41.59)
Kostas Biliouris
·
BMO Capital
Citigroup Initiates Coverage On Beam Therapeutics with Buy Rating, Announces Price Target of $62
$62.00
(was $48.19)
Citigroup
Credit Suisse Initiates Coverage On Beam Therapeutics with Neutral Rating, Announces Price Target of $62
$62.00
(was $39.83)
Credit Suisse